Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cytokinetics (CYTK) Cash & Current Investments: 2009-2025

Historic Cash & Current Investments for Cytokinetics (CYTK) over the last 17 years, with Sep 2025 value amounting to $962.5 million.

  • Cytokinetics' Cash & Current Investments fell 4.89% to $962.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $3.8 billion, marking a year-over-year increase of 16.08%. This contributed to the annual value of $1.1 billion for FY2024, which is 74.91% up from last year.
  • Latest data reveals that Cytokinetics reported Cash & Current Investments of $962.5 million as of Q3 2025, which was up 12.17% from $858.1 million recorded in Q2 2025.
  • In the past 5 years, Cytokinetics' Cash & Current Investments ranged from a high of $1.1 billion in Q4 2024 and a low of $350.3 million during Q2 2021.
  • Its 3-year average for Cash & Current Investments is $810.0 million, with a median of $858.1 million in 2025.
  • As far as peak fluctuations go, Cytokinetics' Cash & Current Investments skyrocketed by 92.83% in 2021, and later plummeted by 37.81% in 2023.
  • Quarterly analysis of 5 years shows Cytokinetics' Cash & Current Investments stood at $471.6 million in 2021, then soared by 66.27% to $784.2 million in 2022, then dropped by 21.55% to $615.2 million in 2023, then soared by 74.91% to $1.1 billion in 2024, then declined by 4.89% to $962.5 million in 2025.
  • Its Cash & Current Investments stands at $962.5 million for Q3 2025, versus $858.1 million for Q2 2025 and $938.2 million for Q1 2025.